|
|
|
FMI - Foundation Medicine, Inc.
Foundation Medicine, Inc. (FMI) is a publicly traded biotechnology company that specializes in molecular information to help guide cancer treatment decisions. The company's core product, FoundationOne, is a genomic profiling test that analyzes more than 300 cancer-related genes to provide physicians with information about the unique genomic alterations of a patient's cancer, which can inform treatment decisions.
Founded in 2010 and headquartered in Cambridge, Massachusetts, FMI became a public company in 2013 and is traded on the NASDAQ stock exchange under the symbol FMI. In addition to FoundationOne, the company also offers other genomic tests and services, including FoundationACT, which analyzes circulating tumor DNA in blood samples to monitor treatment response and detect emerging resistance mutations, and FoundationOne Liquid, a non-invasive test that analyzes circulating tumor DNA from a blood sample.
FMI collaborates with a wide range of pharmaceutical and biotechnology companies to advance precision medicine and improve patient outcomes. The company has partnerships with several major cancer centers, including Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center. In 2020, FMI was acquired by Roche Holdings AG, a Swiss multinational healthcare company, for approximately $2.4 billion.
|
|
|
|
|
